-- 周三,瑞士股市指数收涨1.77%,继续保持上涨势头,原因是人们对中东战争即将结束的希望重燃。 据包括Axios和路透社在内的多家媒体援引消息人士报道,美国和伊朗据称即将就一份仅有14条内容的谅解备忘录达成协议,以结束这场战争。与此同时,美国总统特朗普在Truth Social平台上发帖称,如果伊朗“同意交出已达成协议的物品”,战争和封锁将会结束。他还警告说,如果双方未能达成协议,轰炸的规模和强度将“远超以往”。 在瑞士国内,4月份瑞士私营部门状况有所改善,KOF商业形势指标从上月的16.6升至18.3。 瑞士经济研究所KOF表示:“制造业商业景气指标已从3月份的下滑中全面恢复。项目工程行业的指标上升幅度更大,批发贸易行业的指标上升幅度则较为温和。其他服务业和零售业也呈现温和回升的态势。”该研究所还指出:“然而,未来六个月的商业前景总体上趋于疲软,尤其是在酒店业、批发贸易和制造业。” 企业方面,罗技国际(LOGN.SW)2026财年净利润同比增长至7.112亿美元,高于上年同期的6.315亿美元;净销售额也从45.5亿美元增至48.4亿美元。这家瑞士计算机外设和软件公司的股价在交易日结束时下跌了0.40%。 瑞士眼科护理产品集团爱尔康(Alcon,股票代码:ALC.SW)股价收盘下跌10.96%,原因是其第一季度净利润同比大幅下滑,从3.5亿美元降至1.89亿美元。营业利润下降38%至2.92亿美元,主要受效率提升计划相关成本、无形资产减值支出以及新增关税的影响。另一方面,净销售额同期有所增长。 AlphaValue/Baader Europe的分析师在一份报告中指出:“尽管爱尔康在其目标市场占据主导地位,但其投资前景取决于利润率的提升,而利润率的提升存在执行风险。眼科市场的增长虽然在一定程度上具有粘性,但仍被限制在个位数百分比左右。因此,我们预计爱尔康将在未来几个季度/几年内寻求非内生性增长,尤其考虑到其拟于2026年1月终止对STAAR Surgical的收购。” “虽然目前爱尔康的股价有 12% 的上涨空间,但为了获得更丰厚的回报,投资者或许应该等待股价进一步回调。”
Related Articles
Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%